Nonalcoholic fatty liver disease and hepatocellular carcinoma

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1151-1160

  Zoller, Heinz ^a   Tilg, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Carcinogenesis; Fatty liver; Hepatoma; Metabolic liver disease; Primary liver tumor

Indexed keywords

IRON;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DIABETES MELLITUS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HUMAN; INTESTINE FLORA; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE COURSE; INCIDENCE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; INCIDENCE; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84958580773     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.01.010     Document Type: Article

References (89)

1. [1] Tannapfel, A., Denk, H., Dienes, H.P., Langner, C., Schirmacher, P., Trauner, M., et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 458 (2011), 511–523.
2. [2] Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
3. [3] Powell, E.E., Cooksley, W.G., Hanson, R., Searle, J., Halliday, J.W., Powell, L.W., The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990), 74–80.
4. [4] Abdelmalek, M., Ludwig, J., Lindor, K.D., Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 20 (1995), 127–130.
5. [5] Teli, M.R., James, O.F., Burt, A.D., Bennett, M.K., Day, C.P., The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995), 1714–1719.
6. [6] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
7. [7] McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P., Anstee, Q.M., Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
8. [8] Guzman, G., Brunt, E.M., Petrovic, L.M., Chejfec, G., Layden, T.J., Cotler, S.J., Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 132 (2008), 1761–1766.
9. [9] Leung, C., Yeoh, S.W., Patrick, D., Ket, S., Marion, K., Gow, P., et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 21 (2015), 1189–1196.
10. [10] White, D.L., Kanwal, F., El-Serag, H.B., Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10 (2012), 1342–1359.e2.
11. [11] Ratziu, V., Bonyhay, L., Di Martino, V., Charlotte, F., Cavallaro, L., Sayegh-Tainturier, M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002), 1485–1493.
12. [12] Hui, J.M., Kench, J.G., Chitturi, S., Sud, A., Farrell, G.C., Byth, K., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003), 420–427.
13. [13] Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J.M., Saracco, G., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54 (2011), 1208–1216.
14. [14] Yatsuji, S., Hashimoto, E., Tobari, M., Taniai, M., Tokushige, K., Shiratori, K., Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24 (2009), 248–254.
15. [15] Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
16. [16] Loria, P., Lonardo, A., Anania, F., Liver and diabetes. A vicious circle. Hepatol Res 43 (2013), 51–64.
17. [17] Sorrentino, P., D'Angelo, S., Ferbo, U., Micheli, P., Bracigliano, A., Vecchione, R., Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 50 (2009), 351–357.
18. [18] Ascha, M.S., Hanouneh, I.A., Lopez, R., Tamimi, T.A., Feldstein, A.F., Zein, N.N., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51 (2010), 1972–1978.
19. [19] Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 (2011), 428–433 [quiz e50].
20. [20] Takuma, Y., Nouso, K., Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 16 (2010), 1436–1441.
21. [21] Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003), 1625–1638.
22. [22] Hassan, M.M., Abdel-Wahab, R., Kaseb, A., Shalaby, A., Phan, A.T., El-Serag, H.B., et al. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 149 (2015), 119–129.
23. [23] Saunders, D., Seidel, D., Allison, M., Lyratzopoulos, G., Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther 31 (2010), 1051–1063.
24. [24] Karagozian, R., Derdak, Z., Baffy, G., Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63 (2014), 607–617.
25. [25] Adami, H.O., Chow, W.H., Nyren, O., Berne, C., Linet, M.S., Ekbom, A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88 (1996), 1472–1477.
26. [26] Wideroff, L., Gridley, G., Mellemkjaer, L., Chow, W.H., Linet, M., Keehn, S., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89 (1997), 1360–1365.
27. [27] Lagiou, P., Kuper, H., Stuver, S.O., Tzonou, A., Trichopoulos, D., Adami, H.O., Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92 (2000), 1096–1099.
28. [28] Lagiou, P., Rossi, M., Tzonou, A., Georgila, C., Trichopoulos, D., La Vecchia, C., Glycemic load in relation to hepatocellular carcinoma among patients with chronic hepatitis infection. Ann Oncol 20 (2009), 1741–1745.
29. [29] Zhou, Y.M., Zhang, X.F., Wu, L.P., Sui, C.J., Yang, J.M., Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol 20 (2014), 12615–12620.
30. [30] Nelson, J.E., Wilson, L., Brunt, E.M., Yeh, M.M., Kleiner, D.E., Unalp-Arida, A., et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53 (2011), 448–457.
31. [31] Pei, Y., Zhang, T., Renault, V., Zhang, X., An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin (Shanghai) 41 (2009), 1–15.
32. [32] Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 (2015), 505–511.
33. [33] Zain, S.M., Mohamed, R., Cooper, D.N., Razali, R., Rampal, S., Mahadeva, S., et al. Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. PLoS One, 9, 2014, e95604.
34. [34] Lipowsky, G., Bischoff, F.R., Schwarzmaier, P., Kraft, R., Kostka, S., Hartmann, E., et al. Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J 19 (2000), 4362–4371.
35. [35] Liang, X.T., Pan, K., Chen, M.S., Li, J.J., Wang, H., Zhao, J.J., et al. Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 26 (2011), 544–549.
36. [36] Zhang, H., Wei, S., Ning, S., Jie, Y., Ru, Y., Gu, Y., Evaluation of TGFbeta, XPO4, elF5A2 and ANGPTL4 as biomarkers in HCC. Exp Ther Med 5 (2013), 119–127.
37. [37] Choi, J.K., Choi, J.Y., Kim, D.G., Choi, D.W., Kim, B.Y., Lee, K.H., et al. Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett 565 (2004), 93–100.
38. [38] Hernandez-Vargas, H., Lambert, M.P., Le Calvez-Kelm, F., Gouysse, G., McKay-Chopin, S., Tavtigian, S.V., et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One, 5, 2010, e9749.
39. [39] Liu, M., Cui, L.H., Li, C.C., Zhang, L., Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis. Eur J Cancer Prev, 2015.
40. [40] Bao, L., Yan, Y., Xu, C., Ji, W., Shen, S., Xu, G., et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337 (2013), 226–236.
41. [41] Tumaneng, K., Schlegelmilch, K., Russell, R.C., Yimlamai, D., Basnet, H., Mahadevan, N., et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 14 (2012), 1322–1329.
42. [42] Takaki, Y., Saito, Y., Takasugi, A., Toshimitsu, K., Yamada, S., Muramatsu, T., et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci 105 (2014), 1254–1260.
43. [43] De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G.P., Saccomanno, S., Candelaresi, C., et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One, 9, 2014, e97136.
44. [44] Nishiyama, M., Wands, J.R., Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 183 (1992), 280–285.
45. [45] Whitman, M., Downes, C.P., Keeler, M., Keller, T., Cantley, L., Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332 (1988), 644–646.
46. [46] Fruman, D.A., Rommel, C., PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13 (2014), 140–156.
47. [47] Kudo, Y., Tanaka, Y., Tateishi, K., Yamamoto, K., Yamamoto, S., Mohri, D., et al. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol 55 (2011), 1400–1408.
48. [48] Watanabe, S., Horie, Y., Suzuki, A., Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol Res 33 (2005), 161–166.
49. [49] Vivanco, I., Sawyers, C.L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002), 489–501.
50. [50] Kitisin, K., Ganesan, N., Tang, Y., Jogunoori, W., Volpe, E.A., Kim, S.S., et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26 (2007), 7103–7110.
51. [51] Campbell, J.S., Hughes, S.D., Gilbertson, D.G., Palmer, T.E., Holdren, M.S., Haran, A.C., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 102 (2005), 3389–3394.
52. [52] Fan, C.Y., Pan, J., Usuda, N., Yeldandi, A.V., Rao, M.S., Reddy, J.K., Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273 (1998), 15639–15645.
53. [53] Huang, J., Viswakarma, N., Yu, S., Jia, Y., Bai, L., Vluggens, A., et al. Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol 179 (2011), 703–713.
54. [54] Wolf, M.J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., et al. Metabolic activation of intrahepatic CD8 + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26 (2014), 549–564.
55. [55] Vucur, M., Roderburg, C., Bettermann, K., Tacke, F., Heikenwalder, M., Trautwein, C., et al. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget 1 (2010), 373–378.
56. [56] Locatelli, I., Sutti, S., Vacchiano, M., Bozzola, C., Albano, E., NF-kappaB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. Clin Sci (Lond) 124 (2013), 279–287.
57. [57] Maeda, S., Kamata, H., Luo, J.L., Leffert, H., Karin, M., IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005), 977–990.
58. [58] Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004), 461–466.
59. [59] Karin, M., NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol, 1, 2009, a000141.
60. [60] Martinez-Chantar, M.L., Corrales, F.J., Martinez-Cruz, L.A., Garcia-Trevijano, E.R., Huang, Z.Z., Chen, L., et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 16 (2002), 1292–1294.
61. [61] Cadoret, A., Ovejero, C., Saadi-Kheddouci, S., Souil, E., Fabre, M., Romagnolo, B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 61 (2001), 3245–3249.
62. [62] Harada, N., Miyoshi, H., Murai, N., Oshima, H., Tamai, Y., Oshima, M., et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 62 (2002), 1971–1977.
63. [63] Nejak-Bowen, K.N., Thompson, M.D., Singh, S., Bowen, W.C. Jr., Dar, M.J., Khillan, J., et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 51 (2010), 1603–1613.
64. [64] Tan, X., Apte, U., Micsenyi, A., Kotsagrelos, E., Luo, J.H., Ranganathan, S., et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 129 (2005), 285–302.
65. [65] Newell, P., Villanueva, A., Friedman, S.L., Koike, K., Llovet, J.M., Experimental models of hepatocellular carcinoma. J Hepatol 48 (2008), 858–879.
66. [66] Liu, Y.L., Patman, G.L., Leathart, J.B., Piguet, A.C., Burt, A.D., Dufour, J.F., et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61 (2014), 75–81.
67. [67] Liu, Y.L., Reeves, H.L., Burt, A.D., Tiniakos, D., McPherson, S., Leathart, J.B., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 5, 2014, 4309.
68. [68] Ren, Z., Xu, S., Jiang, J., Zheng, S., A Novel Diagnosis for Early Hepatocellular Carcinoma Based On Intestinal Microbiome. 21st Annual Meeting of the International Liver Transplant Society, Chicago, IL, 2015.
69. [69] Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
70. [70] Yoshimoto, S., Loo, T.M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
71. [71] Chen, H.P., Shieh, J.J., Chang, C.C., Chen, T.T., Lin, J.T., Wu, M.S., et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62 (2013), 606–615.
72. [72] Adams, L.A., Crawford, D.H., Stuart, K., House MJ, St Pierre, T.G., Webb, M., et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology 61 (2015), 1555–1564.
73. [73] Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43 (2006), 682–689.
74. [74] Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002), 134–140.
75. [75] Hashimoto, K., Hirai, M., Kurosawa, Y., Identification of a mouse homolog for the human hereditary haemochromatosis candidate gene. Biochem Biophys Res Commun 230 (1997), 35–39.
76. [76] Hai, S., Kubo, S., Shuto, T., Tanaka, H., Takemura, S., Yamamoto, T., et al. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 36 (2006), 390–394.
77. [77] Maeda, T., Hashimoto, K., Kihara, Y., Ikegami, T., Ishida, T., Aimitsu, S., et al. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis. Hepatogastroenterology 55 (2008), 1404–1406.
78. [78] Kawada, N., Imanaka, K., Kawaguchi, T., Tamai, C., Ishihara, R., Matsunaga, T., et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44 (2009), 1190–1194.
79. [79] Malik, S.M., Gupte, P.A., de Vera, M.E., Ahmad, J., Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 7 (2009), 800–806.
80. [80] Chagas, A.L., Kikuchi, L.O., Oliveira, C.P., Vezozzo, D.C., Mello, E.S., Oliveira, A.C., et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz J Med Biol Res 42 (2009), 958–962.
81. [81] Kaneto, H., Sasaki, S., Yamamoto, H., Itoh, F., Toyota, M., Suzuki, H., et al. Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48 (2001), 372–377.
82. [82] Liu, F., Li, H., Chang, H., Wang, J., Lu, J., Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis. Tumori 101 (2015), 206–214.
83. [83] Zhang, Y.J., Ahsan, H., Chen, Y., Lunn, R.M., Wang, L.Y., Chen, S.Y., et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 35 (2002), 85–92.
84. [84] Feng, Q., Stern, J.E., Hawes, S.E., Lu, H., Jiang, M., Kiviat, N.B., DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 88 (2010), 287–292.
85. [85] Nishida, N., Kudo, M., Nagasaka, T., Ikai, I., Goel, A., Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 56 (2012), 994–1003.
86. [86] Wong, V.W., Wong, G.L., Choi, P.C., Chan, A.W., Li, M.K., Chan, H.Y., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59 (2010), 969–974.
87. [87] Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59 (2013), 550–556.
88. [88] Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654 [quiz e39-40].
89. [89] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.